Our results suggest that IMP3 is a novel regulator of /MEK1/ERK signaling pathway through stabilizing MEKK1 mRNA, and suggest that IMP3, combined with MEK1, is a potential therapeutic target for anti-metastatic strategies for CRC. This evidence concerns the gene MAP2K1 and colorectal carcinoma.